RARE News Alert Ultragenyx Pharmaceutical Inc. (RARE) 54.72 09/19/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2014 at 6:24 PM

Ultragenyx Pharmaceutical Inc. (RARE) 54.72 $RARE

IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.

Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.

Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Wed Sep 03, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Innsbruck, Austria.

Ultragenyx to Present at the Baird Health Care Conference
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Robert W. Baird & Co. 2014 Health Care Conference on September 3, 2014 at 1:45pm ET in New York.

3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Tue Aug 26, 6:00AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:41AM CDT
Ultragenyx (RARE) Shares March Higher, Can It Continue?

Company News for August 12, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:10AM CDT
Companies in the News are: DF,SYY,VHI,RARE

Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the second quarter ended June 30, 2014.

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

Why Ultragenyx Pharmaceutical (RARE) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 7:30AM CDT
Ultragenyx Pharmaceutical (RARE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 06, 8:04AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Wedbush PacGrow Life Sciences Management Access Conference on August 13, 2014 at 3:40pm ET in New York and at the Canaccord Genuity Growth Conference on August 14, 2014 at 10:30am ET in Boston.

Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
GlobeNewswire - Tue Aug 05, 8:01AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin (UX007). The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland.

Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.

3 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 31, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President
GlobeNewswire - Wed Jul 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's CEO, and will serve on the Senior Management Team.

Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.

Ultragenyx concludes public offering of 2.32m common shares, including exercise of underwriters' option
M2 - Tue Jul 15, 8:19AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) revealed on Monday the completion of its public offering of 2,319,951 shares of common stock.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ID Plans Secures Polaris Investment for Real Estate Boost

New Moves in Real Estate Tech Can you smell opportunity? Because it’s in the air down in Tampa where ID Plans just inked a deal with Polaris Growth Fund. We’re talking some serious private equity backing here aimed at ramping up what ID Plans can lay down in the commercial real estate sector. If you're not on this ride yet, it might be time to take a closer look....

ESI Motion's Role in Lockheed's Missile Defense Program

ESI Motion's Solar Drive Tech Joins the Defense Arena Picture this: ESI Motion Inc. just inked a deal with Lockheed Martin to supply Solar Array Drive Electronics (SADE) technology—a serious move in space tech. Now, ESI isn't just playing in the local Simi Valley sandbox; they're thrusting their tech into something much more critical—national defense. We're talking...

Right College Fit Crucial for Graduation Rates

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Beta Bionics: Investors on Edge, Legal Moves Underway

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

David Cornue Brings Story Insights to SXSW 2027

Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...

?atwogang Leads Tiltify's Impact Creator Class of 2026

Charity Meets Creativity: A New Era Unveiled Who would have thought? Charitable fundraising is no longer just about writing checks. It's about creativity, community, and leveraging tech to drive change. Enter Tiltify's Creator Impact Class of 2026—proof that we're living in a brave new world where internet creators are the kings and queens of giving. ?atwogang Takes...

Bandwidth Welcomes Chip Schroeder: Key Board Makeover

Turning the Page at Bandwidth Bandwidth Inc. (NASDAQ:BAND) just shook up its executive roster by bringing in a heavy hitter. Chip Schroeder's landing on the board is a bold move from a strategic player in the cloud communications space. This guy's not your average board member; he's a veteran navigator through stormy market waters, and at Bandwidth, it seems he'll be...

Palmdale Propane Expands with Affordable Gas Buy

Propane Power Play in Florida's Market Here's a little tune you don't hear every day: two local businesses tangoing to the beat of expansion without making a public peep about the price. Palmdale Propane, a powerhouse under the Palmdale Oil umbrella, just snapped up Affordable Gas, a local player from Belle Glade, Florida. This acquisition strengthens its grip on the...

SELCO and Numerica Unite: A Merger That's All Heart

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Domino’s Faces Legal Heat: Investors' Eyes On DPZ

Domino's Pizza Under the Legal Microscope Picture this, folks: Domino's Pizza (NASDAQ: DPZ) is caught in a legal whirlwind that might give its shareholders a rollercoaster of a read in the coming weeks. On the docket is a serious probe led by Johnson Fistel, a law outfit with quite the reputation for defending shareholder interests. The focus? Whether certain hot shots at...